EGFR and non-small cell lung carcinoma: Moreover, another anti-EGFR monoclonal antibody, necitumumab, when used in combination with chemotherapy as the first-line therapy, achieved a longer OS (11.5 months vs. 9.9 months) than chemotherapy alone among advanced squamous NSCLC patients [205].